Patient Buzz Series: Gen Z and Sun Protection Myths
You may want to make an extra effort to encourage your young adult patients to protect their skin from the sun. Recent surveys, as noted in The New York Times, showed that adults born after 1997 – those considered in Gen Z – were more likely to believe sun safety myths, including that daily sunscreen usage is more harmful than sun exposure.
Experts say that misinformation in this age group …
You may want to make an extra effort to encourage your young adult patients to protect their skin from the sun. Recent surveys, as noted in The New York Times, showed that adults born after 1997 – those considered in Gen Z – were more likely to believe sun safety myths, including that daily sunscreen usage is more harmful than sun exposure.
Experts say that misinformation in this age group … Continue reading "Patient Buzz Series: Gen Z and Sun Protection Myths"
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition.1 Due to its longer duration of action, it is typically administered subcutaneously once weekly. The safety profile of semaglutide is similar to … 
Next Steps in Derm and the Journal of Drugs in Dermatology, in partnership with the Dermatology Education Foundation (DEF) and Physicians Resources, interviewed Dr. David E. Cohen (Charles C. and Dorothea E. Harris Professor of Dermatology, Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine) on patch testing for allergic contact dermatitis in atopic dermatitis pati … 
Chromate causes persistent, difficult to treat irritant and allergic contact dermatitis in cement-handling occupational workers. When therapeutics such as topical corticosteroids, topical calcineurin inhibitors, phototherapy and immune-modulating treatments like methotrexate fail, many patients are advised that avoidance may be the only remaining option – an option that may be particularly chall … 
The following two cases presented by JDD authors Ryan A. Gall MD, John D. Peters MD, and Alyson J. Brinker MD add to the growing literature supporting the use of dupilumab in the treatment of patients with recalcitrant dyshidrotic eczema, both with and without diagnosed contact allergens.
Introduction
Dyshidrotic eczema, also known as dyshidrosis or pompholyx when involving larger bullae, is a c … 